Autoantibodies specifically detected in patients with polymyositis/dermatomyositis

Japanese Journal of Clinical Immunology

Volumn 29, Issue 2, 2006, Pages 85-93

  Sato, Shinji ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Clinically amyopathic dermatomyositis (C ADM); Polymyositis dermatomyositis (PM DM); Rapidly progressive interstitial lung disease

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CADM 140 PEPTIDE, HUMAN; CADM-140 PEPTIDE, HUMAN; HISTIDINE TRANSFER RNA LIGASE; MI 2 ANTIBODIES; MI-2 ANTIBODIES; PEPTIDE; SIGNAL RECOGNITION PARTICLE;

ADULT; BLOOD; DERMATOMYOSITIS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULAR MIMICRY; POLYMYOSITIS; PROGNOSIS; REVIEW;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HISTIDINE-TRNA LIGASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR MIMICRY; PEPTIDES; POLYMYOSITIS; PROGNOSIS; SIGNAL RECOGNITION PARTICLE;

EID: 33745174175     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.29.85     Document Type: Article

References (39)

1. th Ed., Lea and Febiger, Philadelphia, pp. 742, 1979.
2. Targoff IN: Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin N Am 28: 859–890, 2002.
3. Targoff IN, et al.: Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 9: 527–535, 1997.
4. Targoff IN: Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 12 (6): 475–481, 2000.
5. Hirakata M, et al.: Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 162: 2315–2320, 1999.
6. Sato S, et al.: Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA) autoantibodies. Clin Exp Rheumatol 23: 609–615, 2005.
7. Lef RL, et al.: Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1andanti-signal recognition particle autoantibodies. Arthritis Rheum 34: 1391–1396, 1991.
8. Mathews MB, et al.: Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity. Nature 304: 177–179, 1983.
9. Christensen ML, et al.: Prevalence of Coxackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 29: 1365–1370, 1986.
10. Walker EJ, et al.: Sequence homology between encephalomyocarditis virus protein VPI and histidyl-tRNA synthetase supports a hypothesis of molecular mimicry in polymyositis. Med Hypotheses 25: 21–25, 1988.
11. Walker EJ, et al.: Polymyositis and molecular mimicry, a mechanism of autoimmunity. Lancet 2: 605–607, 1986.
12. Casciola-Rosen L, et al.: Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J Exp Med 190: 815–826, 1999.
13. Levine SM, et al.: Anti-aminoacyl tRNA synthetase immune responses: Insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheeumatol 15: 708–713, 2003.
14. Howard OM, et al.: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors of T lymphocytes and immature dendritic cells. J Exp Med 196: 781–791, 2002.
15. Arnett FC, et al.: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 39: 1507–1518, 1996.
16. Okada N, et al.: Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol 138: 3219–3223, 1987.
17. Satoh T, et al.: Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 32: 1727–1733, 2005.
18. Kao AH, et al.: Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy: Arthritis Rheum 50: 209–215, 2004.
19. Love LA et al.: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70: 360–374, 1991.
20. Nilasena DS et al.: Analysis of the Mi-2autoantigen of dermatomyositis. Arthritis Rheum 38: 1534–1538, 1994.
21. Seeling HP et al.: The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved transcriptional activation. Arthritis Rheum 38: 1389–1399, 1995.
22. Komura K et al.: Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 40: 215–217, 2005.
23. Mierau R, et al.: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 39: 868–876, 1996.
24. Krain L: Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol 111: 241–245, 1975.
25. Euwer RL, et al.: Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 24: 959–966, 1991.
26. Bohan A, et al.: Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56: 255–286, 1977.
27. Euwer RL, et al.: Amyopathic dermatomyositis: A review. J Invest Dermatol 100: 124S-127S, 1993.
28. Callen JP, et al.: Amyopathic dermatomyositis (dermatomyositis sine myositis). JAm Acad Dermatol 26: 505–506, 1992.
29. Dawkins MA, et al.: Dermatomyositis: A dermatology-based case series. J Am Acad Dermtol 38: 397–404, 1998.
30. Sontheimer RD: Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626–636, 2002.
31. Lee CS, et al.: Idiopathic inflammatory Myopathy with Diffuse Alveolar Damage. Clin Rheumatol 21: 391–396, 2002.
32. Aoki M, et al.: Cyclosporin-A ameliorated interstitial pneumonitis in a patient with amyopathic dermatomyositis. Mod Rheumatol 12: 342–345, 2002.
33. Sato S, et al.: Clinical and immunological associations of autoantibodies to the 140 kDa polypeptide (the US autoantigen) in patients with clinically amyopathic dermatomyositis [abstract]. Arthritis Rheum 48 (Suppl 9): S102, 2003.
34. Sato S, et al.: Autoantibodies to a 140-kd poly-peptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52 (5): 1571–1576, 2005.
35. Targof IN, et al.: Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis [abstract]. Arthritis Rheum 43 (Suppl 9): S194, 2000.
36. Targoff IN, et al.: A novel dermatomyositis-as-sociated autoantibody directed against a 155 kd protein [abstract]. Arthritis Rheum 43 (Suppl 9): S175, 2000.
37. Mamyrova G, et al.: Distinguishing clinical features of JDM associated with a myositis associated autoantibody (MAA) directed against a 155 kd protein [abstract]. Arthritis Rheum 47 (Suppl 9): S514, 2003.
38. Oddis CV, et al.: Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 40 (Suppl 9): S139, 1997.
39. Casciola-Rosen LA, et al.: The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 44: 389–396, 2001.